Celgene Corp (CELG)

CELG (NASDAQ:Drugs)
$89.46
neg -2.06
-2.25%
Today's Range: 88.22 - 91.05 | CELG Avg Daily Volume: 4,452,700
Last Update: 09/15/14 - 4:14 PM EDT
Volume: 4,901,789
YTD Performance: 8.33%
Open: $91.00
Previous Close: $91.52
52 Week Range: $66.85 - $96.44
Oustanding Shares: 799,510,100
Market Cap: 73,522,948,796
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 17 16 17 18
Moderate Buy 1 1 1 1
Hold 4 4 3 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.41 1.43 1.33 1.39
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 53.16
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
53.16 53.00 28.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.24% 22.32% 203.45%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.90 0.79 0.21
Net Income -0.40 0.65 0.18
EPS 2.00 0.84 0.22
Earnings for CELG:
EBITDA 2.35B
Revenue 6.49B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.82 $0.87 $3.20 $4.38
Number of Analysts 4 4 3 4
High Estimate $0.85 $0.91 $3.24 $4.94
Low Estimate $0.79 $0.85 $3.17 $4.09
Prior Year $0.69 $0.67 $2.68 $3.20
Growth Rate (Year over Year) 17.99% 31.20% 19.28% 37.02%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Carolyn Boroden

 | Sep 14, 2014 | 6:00 PM EDT

Odds are up for an impending upward reversal.

updateCiti Biotech Conf.

Sep 4, 2014 | 7:37 AM EDT

Citi Biotech Conference 

By

Jim Cramer

 | Sep 2, 2014 | 6:53 AM EDT

Yep, the bets for the rest of 2014 are being placed.

By

Timothy Collins

 | Aug 26, 2014 | 11:54 AM EDT
Checking two biotech charts.
By

Jim Cramer

 | Aug 14, 2014 | 12:18 PM EDT

Amgen's gain is pure insanity from a stock picker's point of view.

By

Jim Cramer

 | Aug 13, 2014 | 1:18 PM EDT

Biotech stocks are thriving in a slower-growth, low-inflation world.

By

Jim Cramer

 | Aug 11, 2014 | 11:49 AM EDT

Like others, it's perennially cautious. And you can profit from that.

By

Jim Cramer

 | Jul 30, 2014 | 11:11 AM EDT

Where what the Fed does allegedly determines everything.

bullishCelgene estimates, target increased at Credit Suisse

Jul 25, 2014 | 8:08 AM EDT

CELG estimates were raised through 2016, Credit Suisse said. Company boosted its guidance. Outperform rating and new $113 price target. 

By

Jim Cramer

 | Jul 24, 2014 | 3:05 PM EDT

Boeing, Celgene and Qualcomm have big upside, though their stocks are lagging.

If you are still long GS, it's time to really ratchet up those stops and it is at extensio...
Is the sell-off in the NASDAQ ( the RUT was down, too, back below its 50 and 200 day movi...
SCTY is trading $67.81, down 8.4% with IV30™ up 9.6%. Conclusion This is a stock and...
The stronger dollar and the removal of most of the ethanol premium, has landed sugar price...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.